Fenofibrate in primary sclerosing cholangitis; a randomized, double‐blind, placebo‐controlled trial
Abstract Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with no medical treatment proven to improve survival and postpone liver transplantation. Previous studies have shown the effectiveness of fibrates in primary biliary cholangitis. The current study prospectively eval...
Main Authors: | Behzad Hatami, Mozhde Mosala, Amir Hossein Hassani, Mohammad Javad Ehsani Ardakani, Samira Gholami, Mohammad Reza Zali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-08-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.984 |
Similar Items
-
Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA
by: Weijia Duan, et al.
Published: (2018-09-01) -
Surrogate markers of bile duct disease progression in primary sclerosing cholangitis – A prospective study with repeated ERCP examinations
by: Martti Färkkilä, et al.
Published: (2024-10-01) -
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
by: Kazufumi Dohmen, et al.
Published: (2021-10-01) -
PREGNANCY WITH PRIMARY SCLEROSING CHOLANGITIS
by: E. A. Alexandrova, et al.
Published: (2016-09-01) -
Neonatal cholestasis due to primary sclerosing cholangitis
by: Naman Sadanand Shetty, et al.
Published: (2016-01-01)